Actively Recruiting

Phase Not Applicable
Age: 18Years - 40Years
All Genders
Healthy Volunteers
NCT04373629

Perceptual Abnormalities and Their Malleability in BDD

Led by Centre for Addiction and Mental Health · Updated on 2025-11-14

146

Participants Needed

1

Research Sites

286 weeks

Total Duration

On this page

Sponsors

C

Centre for Addiction and Mental Health

Lead Sponsor

N

National Institute of Mental Health (NIMH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

A core symptom of body dysmorphic disorder (BDD) is perceptual distortions for appearance, which contributes to poor insight and delusionality, limits engagement in treatment, and puts individuals at risk for relapse. Results from this study will provide a comprehensive mechanistic model of brain, behavioral, and emotional contributors to abnormal perceptual processing, as well as how malleable it is with visual modulation techniques. This will lay the groundwork for next-step translational perceptual retraining approaches.

CONDITIONS

Official Title

Perceptual Abnormalities and Their Malleability in BDD

Who Can Participate

Age: 18Years - 40Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Males or females aged 18 to 40 years
  • Meet DSM-5 criteria for Body Dysmorphic Disorder with a BDD-YBOCS score of 20 or higher
  • Primary appearance concerns focused on the face or head area
  • Medication naive or medication free for at least 8 weeks before enrollment
  • For subclinical BDD: score of 8 or higher on Dysmorphic Concern Questionnaire with face or head concerns
  • Healthy controls aged 18 to 40 years with Dysmorphic Concern Questionnaire score below 8
Not Eligible

You will not qualify if you...

  • Current major Axis I disorders including substance use disorders, except anxiety or depressive disorders; BDD must be primary diagnosis
  • Lifetime history of bipolar disorder or psychotic disorder
  • Use of psychotropic medications except limited sedative/hypnotic or benzodiazepine use (maximum 3 doses/week) and not on training or MRI days
  • Current cognitive-behavioral therapy
  • For subclinical BDD: full DSM-5 criteria for BDD or current Axis I disorders
  • For healthy controls: any current Axis I disorder, lifetime bipolar or psychotic disorder, or psychiatric medication use
  • Neurological disorders
  • Pregnancy
  • Major medical disorders affecting brain metabolism such as diabetes or thyroid disorders
  • Current suicide risk with plan and intent
  • Ferromagnetic implants or devices
  • Visual acuity worse than 20/35 in each eye (corrective lenses allowed)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Centre for Addiction and Mental Health

Toronto, Ontario, Canada, M6J 1H3

Actively Recruiting

Loading map...

Research Team

R

Research Analyst

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here